@Tech2Biotech Released two companion books on China biotech out-licensing last month — for anyone wanting to know more:
Handbook (the mechanics): https://t.co/JbJqy3FloE Novel (same dynamics, as a story): https://t.co/civuLS4nUD
Bundle: https://t.co/GYaVYpjQUX
@Tech2Biotech The slogan says rivalry. The checkbook says supplier. Both are true at once.
And the two deadlines that’ll actually decide the next decade — the OMB grant rule and PDUFA VIII — are the ones nobody’s watching.
@Tech2Biotech Washington’s response: fix the FDA to “beat China.” Bipartisan agreement, a whole reform roadmap.
But while politicians build a fence, investors build a bridge — Western pharma isn’t fighting Chinese drugs, it’s buying them at record pace.
@Tech2Biotech Every medicine has a birthplace — the Phase 1 trial, the first test in a human.
For decades that was the US. Now China runs 32% of the world’s clinical trials, up from 1% in 2009. Their approval cycles run 50–70% faster.
The birthplace is moving offshore.
@Tech2Biotech The US is fighting China in biotech while buying 1 in 3 of its new drugs from them.
$14B → $136B in China-to-West licensing in 4 years.
The fence and the bridge, built at the same time. A thread on the twist nobody’s connecting
Congratulations Keira Kraemer! Keira is heading to the PIAA State Championships in both High Jump and Triple Jump.
Her clearance over 5’3” is a new PR and was good for 4th place. In triple jump, her furthest mark of the day was 37-07.25 which was good for 3rd place! 🥉